Cargando…
A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes
OBJECTIVE: To investigate the genetic influence of 48 type 2 diabetes susceptibility variants on disease progression measured as risk of early prescription redemption of glucose lowering drugs in screen-detected patients with type 2 diabetes. METHODS: We studied type 2 diabetes progression in 1,480...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144838/ https://www.ncbi.nlm.nih.gov/pubmed/25157406 http://dx.doi.org/10.1371/journal.pone.0104837 |
_version_ | 1782332084620099584 |
---|---|
author | Hornbak, Malene Allin, Kristine Højgaard Jensen, Majken Linnemann Lau, Cathrine Juel Witte, Daniel Jørgensen, Marit Eika Sandbæk, Annelli Lauritzen, Torsten Andersson, Åsa Pedersen, Oluf Hansen, Torben |
author_facet | Hornbak, Malene Allin, Kristine Højgaard Jensen, Majken Linnemann Lau, Cathrine Juel Witte, Daniel Jørgensen, Marit Eika Sandbæk, Annelli Lauritzen, Torsten Andersson, Åsa Pedersen, Oluf Hansen, Torben |
author_sort | Hornbak, Malene |
collection | PubMed |
description | OBJECTIVE: To investigate the genetic influence of 48 type 2 diabetes susceptibility variants on disease progression measured as risk of early prescription redemption of glucose lowering drugs in screen-detected patients with type 2 diabetes. METHODS: We studied type 2 diabetes progression in 1,480 patients with screen-detected type 2 diabetes from the ADDITION-Denmark study using information of redeemed prescriptions from the Register of Medicinal Products Statistics from 2001–2009 in Denmark. Patients were cluster randomized by general practitioners, who were randomized to treat type 2 diabetes according to either a conventional or a multifactorial intensive treatment algorithm. We investigated the genetic influence on diabetes progression by constructing a genetic risk score (GRS) of all 48 validated type 2 diabetes susceptibility variants, a GRS of 11 variants linked to β-cell function and a GRS of 3 variants linked to insulin sensitivity and assessed the association between number of risk alleles and time from diagnosis until first redeemed prescription of either any glucose lowering drug or an insulin drug. RESULTS: The GRS linked to insulin sensitivity only nominally increased the risk of an early prescription redemption with an insulin drug by 39% (HR [95% C.I.] = 1.39 [1.09–1.77], p = 0.009] in patients randomized to the intensive treatment group. Furthermore, the strongest univariate predictors of diabetes progression for the intensive treatment group (measured as time to first insulin) were younger age (HR [95% C.I.] = 0.96 [0.93–0.99]), increased BMI (1.05 [1.01–1.09]), increased HbA1c (1.50 [1.36–.66]), increased TG (1.24 [1.11–1.39]) and reduced fasting serum HDL (0.37 [0.17–0.80]) at baseline. Similar results were obtained for the conventional treatment group. CONCLUSION: Higher levels of HbA1c, fasting circulating levels of triglyceride, lower HDL, larger BMI and younger age are significant determinants of early pharmacological intervention in type 2 diabetes. However, known common type 2 diabetes-associated gene variants do not appear to significantly affect disease progression. |
format | Online Article Text |
id | pubmed-4144838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41448382014-08-29 A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes Hornbak, Malene Allin, Kristine Højgaard Jensen, Majken Linnemann Lau, Cathrine Juel Witte, Daniel Jørgensen, Marit Eika Sandbæk, Annelli Lauritzen, Torsten Andersson, Åsa Pedersen, Oluf Hansen, Torben PLoS One Research Article OBJECTIVE: To investigate the genetic influence of 48 type 2 diabetes susceptibility variants on disease progression measured as risk of early prescription redemption of glucose lowering drugs in screen-detected patients with type 2 diabetes. METHODS: We studied type 2 diabetes progression in 1,480 patients with screen-detected type 2 diabetes from the ADDITION-Denmark study using information of redeemed prescriptions from the Register of Medicinal Products Statistics from 2001–2009 in Denmark. Patients were cluster randomized by general practitioners, who were randomized to treat type 2 diabetes according to either a conventional or a multifactorial intensive treatment algorithm. We investigated the genetic influence on diabetes progression by constructing a genetic risk score (GRS) of all 48 validated type 2 diabetes susceptibility variants, a GRS of 11 variants linked to β-cell function and a GRS of 3 variants linked to insulin sensitivity and assessed the association between number of risk alleles and time from diagnosis until first redeemed prescription of either any glucose lowering drug or an insulin drug. RESULTS: The GRS linked to insulin sensitivity only nominally increased the risk of an early prescription redemption with an insulin drug by 39% (HR [95% C.I.] = 1.39 [1.09–1.77], p = 0.009] in patients randomized to the intensive treatment group. Furthermore, the strongest univariate predictors of diabetes progression for the intensive treatment group (measured as time to first insulin) were younger age (HR [95% C.I.] = 0.96 [0.93–0.99]), increased BMI (1.05 [1.01–1.09]), increased HbA1c (1.50 [1.36–.66]), increased TG (1.24 [1.11–1.39]) and reduced fasting serum HDL (0.37 [0.17–0.80]) at baseline. Similar results were obtained for the conventional treatment group. CONCLUSION: Higher levels of HbA1c, fasting circulating levels of triglyceride, lower HDL, larger BMI and younger age are significant determinants of early pharmacological intervention in type 2 diabetes. However, known common type 2 diabetes-associated gene variants do not appear to significantly affect disease progression. Public Library of Science 2014-08-26 /pmc/articles/PMC4144838/ /pubmed/25157406 http://dx.doi.org/10.1371/journal.pone.0104837 Text en © 2014 Hornbak et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Hornbak, Malene Allin, Kristine Højgaard Jensen, Majken Linnemann Lau, Cathrine Juel Witte, Daniel Jørgensen, Marit Eika Sandbæk, Annelli Lauritzen, Torsten Andersson, Åsa Pedersen, Oluf Hansen, Torben A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes |
title | A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes |
title_full | A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes |
title_fullStr | A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes |
title_full_unstemmed | A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes |
title_short | A Combined Analysis of 48 Type 2 Diabetes Genetic Risk Variants Shows No Discriminative Value to Predict Time to First Prescription of a Glucose Lowering Drug in Danish Patients with Screen Detected Type 2 Diabetes |
title_sort | combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in danish patients with screen detected type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144838/ https://www.ncbi.nlm.nih.gov/pubmed/25157406 http://dx.doi.org/10.1371/journal.pone.0104837 |
work_keys_str_mv | AT hornbakmalene acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT allinkristinehøjgaard acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT jensenmajkenlinnemann acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT laucathrinejuel acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT wittedaniel acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT jørgensenmariteika acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT sandbækannelli acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT lauritzentorsten acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT anderssonasa acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT pedersenoluf acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT hansentorben acombinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT hornbakmalene combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT allinkristinehøjgaard combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT jensenmajkenlinnemann combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT laucathrinejuel combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT wittedaniel combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT jørgensenmariteika combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT sandbækannelli combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT lauritzentorsten combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT anderssonasa combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT pedersenoluf combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes AT hansentorben combinedanalysisof48type2diabetesgeneticriskvariantsshowsnodiscriminativevaluetopredicttimetofirstprescriptionofaglucoseloweringdrugindanishpatientswithscreendetectedtype2diabetes |